1. Malaysia Stocks

  2. •

    Healthcare

  3. •

    Medical - Care Facilities
IHH Healthcare Berhad

IHH Healthcare Berhad

Q0F.SI
IHH Healthcare BerhadSG flagStock Exchange of Singapore
2.85
SGD
- -
- -
25.18BMarket Cap
IHH Healthcare Berhad
Q0F.SI
(Stock Exchange of Singapore)

Recent

price

2.85

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.56
0.55
1
0.83
0.9
1.03
1.22
1.35
1.39
1.7
1.53
1.95
2.04
2.38
2.77
2.92
2.94
Revenue per Share
0.01
0.06
0.11
0.08
0.09
0.11
0.07
0.12
0.08
0.06
0.03
0.21
0.18
0.34
0.3
0.24
0.24
Basic EPS, GAAP
0.03
0.03
0.06
0.07
0.09
0.07
-0.04
0.09
0.1
0.16
0.18
0.28
0.22
0.21
0.12
0.21
0.22
Free Cash Flow per Basic Share
- -
- -
- -
- -
0.02
0.03
0.03
0.03
0.03
0.03
0.04
0.04
0.06
0.2
0.1
0.11
0.05
Dividend per Share
0.35
0.95
1.31
1.21
1.28
1.36
1.4
2.48
2.85
2.72
2.7
2.88
2.99
3.13
3.34
3.48
3.48
Book Value per Share
-0.61
0.5
1.07
0.95
1.09
1.18
1.12
1.44
1.6
1.53
1.47
1.49
1.5
1.71
1.59
1.66
1.59
Tangible Book Value per Share
8,053
6,108
6,975
8,114
8,165
8,210
8,229
8,236
8,289
8,772
8,776
8,782
8,803
8,807
8,808
8,828
8,833
Basic Weighted Avg Shares
4,507
3,329
6,962
6,756
7,344
8,455
10,022
11,143
11,521
14,912
13,405
17,132
17,989
20,935
24,383
25,745
26,004
Sales/Revenue/Turnover
8.06
14.02
17
17
18.18
18.07
13.86
16.2
13.09
12.09
10.16
18.33
14.95
20.3
15.99
15.19
15.21
Operating Margin (%)
102
221
509
601
608
690
800
978
939
1,355
1,397
1,317
1,407
1,512
1,734
1,911
1,931
Depreciation Expense
79
373
751
631
754
934
612
970
628
551
289
1,863
1,548
2,952
2,657
2,101
2,115
Net Income, GAAP
64.83
19.75
18.75
16.75
22.76
13.59
30.72
28.74
34.9
50.63
63.73
14.84
25.8
16.25
15.81
23.95
26.97
Effective Tax Rate (%)
1.75
11.22
10.78
9.34
10.27
11.04
6.11
8.7
5.45
3.7
2.16
10.87
8.61
14.1
10.9
8.16
8.13
Profit Margin (%)
-2,847
1,291
837
1,558
1,383
1,414
957
4,119
5,018
2,277
1,731
2,484
1,024
-743
-2,705
-4,737
-4,792
Working Capital
6,536
6,183
3,501
4,170
3,593
6,323
6,853
6,948
9,366
10,118
10,369
9,393
8,974
8,064
10,894
9,689
9,320
LT Debt
3,131
11,025
19,176
19,923
21,313
24,237
23,893
25,901
28,352
28,094
27,035
27,277
29,159
32,359
33,908
34,101
33,436
Total Equity
2.07
2.75
4.75
4.02
4.11
4.64
3.06
3.92
2.68
2.26
1.26
6.91
5.06
8.61
7.22
6.06
5.84
Return on Invested Capital (%)
2.35
3.69
5.56
4.02
4.03
5.22
3.68
5.15
2.78
2.25
1.4
4.98
4.56
7.63
6.34
4.82
4.71
Return on Capital (%)
5.66
8.69
10.05
6.67
7.45
8.66
5.41
6.08
2.85
2.32
1.21
7.6
6
10.96
9.33
6.99
7.02
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
3,079
5,850
5,834
LT Borrowings
10,799
7,734
7,452
LT Finance Leases
1,598
1,955
1,868
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
8,836
8,836
8,836
Market Capitalization
66,048
75,303
79,897

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
6,659
6,657
6,799
Cash, Cash Equivalents & STI
2,152
2,287
2,335
Accounts Receivable, Net
3,591
2,861
3,387
Inventories
788
799
890
Total Current Liabilities
8,657
11,394
11,591
Payables & Accruals
- -
- -
- -
ST Debt
3,079
5,850
5,834
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.59%
4.82%
0.57%
Free Cash Flow
-31.06%
14.21%
81.36%
Net Income, GAAP
51.65%
117.52%
-20.93%
Sales/Revenue/Turnover
12.37%
14.25%
5.59%
Total Cash Common Dividend
28.06%
48.11%
5.22%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5,955
6,093
5,643
6,692
24,383
2025
6,294
6,298
6,570
6,583
25,745
2026
6,553
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.09
0.07
0.06
0.08
0.3
2025
0.06
0.05
0.07
0.06
0.24
2026
0.06
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
0.05
0.1
2025
- -
- -
- -
0.05
0.11
2026
- -
- -
- -
- -
- -
Similar Companies
Rainbow Children's Medicare Limited (RAINBOW.NS)
Bangkok Dusit Medical Services Public Company Limited (BDULF)
JD Health International Inc. (JDHIY)
Artemis Medicare Services Limi (ARTEMISMED.BO)
Ryman Healthcare Limited (RYHTY)
Oceania Healthcare Limited (OCA.NZ)
Business
IHH Healthcare Berhad operates as Asia's largest private healthcare group and one of the world's leading integrated healthcare providers, delivering a full spectrum of services from primary to quaternary care across over 80 hospitals and facilities in 10 countries including Malaysia, Singapore, Türkiye, India, Greater China, and parts of Europe and Southeast Asia. The company offers comprehensive healthcare solutions encompassing outpatient treatments, specialist consultations, emergency care, routine check-ups, vaccinations, local surgeries, acute treatments, and advanced quaternary procedures; it also provides ancillary services such as diagnostic laboratories, imaging centres, ambulatory care, post-operative rehabilitation, medical education, and hospital project management through its trusted brands including Acibadem, Mount Elizabeth, Prince Court, Gleneagles, Fortis, Pantai, and Parkway. Supported by over 70,000 employees, IHH Healthcare targets upmarket patients, medical tourists, and diverse customer segments in its key markets, with headquarters in Kuala Lumpur, Malaysia, where it traces origins to 1974 and lists on Bursa Malaysia and the Singapore Exchange. Recent developments include the acquisition of Island Hospital in Penang, Malaysia, for approximately $900 million in late 2024 to expand its domestic network to 18 hospitals and capture more medical tourism; a mandatory open offer launched in October 2025 to acquire an additional 26.1% stake in India's Fortis Healthcare Ltd alongside preferential allotments in Fortis Malar Hospitals; the purchase of Bayindir Hospitals and six dental clinics in Türkiye; openings and expansions such as Acibadem Kartal and Acibadem Maslak hospitals; launch of a SGD 80 million Innovation Fund with investments in startups like Leo Cancer Care, Belun Technology, Doctor Anywhere, US2.ai, Lucence, and Intellect; and a SGD 5 million Research Grant & Innovation Sandbox programme initiated in March 2025 to foster clinical research in oncology and chronic diseases over five years. These initiatives align with IHH's cluster strategy for organic growth, targeting 4,000 additional beds by 2028, and its active pursuit of value-accretive mergers and acquisitions in Malaysia, India, Türkiye, and Europe under Group CEO Prem Kumar Nair.